Literature DB >> 7012988

Cutaneous and soft-tissue manifestations of sepsis due to gram-negative enteric bacilli.

D M Musher.   

Abstract

Four patterns of tissue involvement can be distinguished in sepsis due to gram-negative enteric bacilli. When intense local inflammation predominates, cellulitis or thrombophlebitis results, often with venous or arterial obstruction. Bacteria are present in the affected tissues, but not in sufficient numbers to be seen microscopically. When bacterial proliferation is unchecked by an appropriate leukocyte response, ecthyma gangrenosum, erythema multiforme, or diffuse bullous lesions may occur with minimal clinical or histologic signs of inflammation. In symmetric peripheral gangrene associated with disseminated intravascular coagulation, bland fibrinous deposits are seen in small vessels but neither inflammatory cells nor bacteria are present. The fourth kind of lesion is that seen in bacterial endocarditis. In all four patterns a vascular component is prominent clinically and histologically. The pathogenesis of these lesions is multifactorial; in each individual case the interaction between bacterial and host factors probably determines which clinical picture will result. The appearance of symmetric soft tissue lesions of the extremities in the absence of predisposing local conditions suggests the possibility of sepsis due to gram-negative bacilli, especially if other clinical features indicate that sepsis might be present.

Entities:  

Mesh:

Year:  1980        PMID: 7012988     DOI: 10.1093/clinids/2.6.854

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

1.  Inland presentation of Vibrio vulnificus primary septicemia and necrotizing fasciitis.

Authors:  R D Jenkins; J M Johnston
Journal:  West J Med       Date:  1986-01

2.  Bacteremia and subcutaneous abscess caused by Proteus penneri in a neutropenic host.

Authors:  H D Engler; K Troy; E J Bottone
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

Review 3.  Cellulitis: A Review of Current Practice Guidelines and Differentiation from Pseudocellulitis.

Authors:  Michelle A Boettler; Benjamin H Kaffenberger; Catherine G Chung
Journal:  Am J Clin Dermatol       Date:  2021-12-13       Impact factor: 7.403

Review 4.  A case of cellulitis complicating Campylobacter jejuni subspecies jejuni bacteremia and review of the literature.

Authors:  A Monselise; D Blickstein; I Ostfeld; R Segal; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-24       Impact factor: 3.267

5.  Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum.

Authors:  E J Bottone; M Reitano; J M Janda; K Troy; J Cuttner
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

6.  Gram-negative bacillary cellulitis in patients with hepatic cirrhosis.

Authors:  J M Corredoira; J Ariza; R Pallarés; J Carratalá; P F Viladrich; G Rufí; R Verdaguer; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

7.  Labial ecthyma gangrenosum in an immunocompromised infant with leukemia: heightening awareness for the urologist.

Authors:  Jose Pulido; Patrick McMahon; James R Treat; John Gunselman; Gregory E Tasian; Sarah K Tasian
Journal:  Urology       Date:  2012-10-02       Impact factor: 2.649

8.  Heparinase Is Essential for Pseudomonas aeruginosa Virulence during Thermal Injury and Infection.

Authors:  Nyaradzo Dzvova; Jane A Colmer-Hamood; John A Griswold; Abdul N Hamood
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

9.  Emergence of bactericidal and opsonizing antibody to Vibrio vulnificus following bacterial infection.

Authors:  D M Musher; M V Hansen; A Goree; F Gyorkey; A J Chapman; R E Baughn
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

10.  Ecthyma gangrenosum of a single limb.

Authors:  George M Varghese; Pushpa Eapen; Susanne Abraham
Journal:  Indian J Crit Care Med       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.